Novavax Inc NVAX
We take great care to ensure that the data presented and summarized in this overview for NOVAVAX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVAX
View all-
State Street Corp Boston, MA16.9MShares$289 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$231 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.43MShares$161 Million0.0% of portfolio
-
Shah Capital Management8.12MShares$139 Million19.75% of portfolio
-
Geode Capital Management, LLC Boston, MA2.59MShares$44.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.87MShares$32 Million0.0% of portfolio
-
Citigroup Inc1.76MShares$30 Million0.01% of portfolio
-
Rafferty Asset Management, LLC New York, NY1.68MShares$28.8 Million0.03% of portfolio
-
Coatue Management LLC New York, NY1.52MShares$26 Million0.03% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.47MShares$25.1 Million0.01% of portfolio
Latest Institutional Activity in NVAX
Top Purchases
Top Sells
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at NVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
7,500
-10.83%
|
$105,000
$14.09 P/Share
|
|
Jun 18
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
7,500
-4.95%
|
$97,500
$13.95 P/Share
|
|
Jun 17
2024
|
Filip Dubovsky President, R&D |
SELL
Open market or private sale
|
Direct |
13,904
-8.79%
|
$194,656
$14.5 P/Share
|
|
Jun 17
2024
|
Filip Dubovsky President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
13,904
+7.73%
|
$83,424
$6.53 P/Share
|
|
Jun 12
2024
|
Margaret G Mcglynn |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
|
Jun 12
2024
|
Richard Douglas |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+13.18%
|
-
|
|
Jun 12
2024
|
Gregg H Alton |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
|
Jun 12
2024
|
Richard J Rodgers |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
|
Jun 12
2024
|
David M Mott |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+11.67%
|
-
|
|
Jun 12
2024
|
Rachel K. King |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+26.06%
|
-
|
|
Jun 12
2024
|
James F Young |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+7.99%
|
-
|
|
May 14
2024
|
Filip Dubovsky President, R&D |
SELL
Open market or private sale
|
Direct |
47,312
-54.85%
|
$615,056
$13.9 P/Share
|
|
May 14
2024
|
Filip Dubovsky President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
19,652
+18.55%
|
$117,912
$6.97 P/Share
|
|
Mar 10
2024
|
John Trizzino EVP, CCO and CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,226
-7.37%
|
$11,130
$5.45 P/Share
|
|
Mar 10
2024
|
John Trizzino EVP, CCO and CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,608
+13.24%
|
-
|
|
Mar 10
2024
|
Filip Dubovsky President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,597
-3.75%
|
$12,985
$5.45 P/Share
|
|
Mar 10
2024
|
Filip Dubovsky President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,376
+7.21%
|
-
|
|
Mar 10
2024
|
James Patrick Kelly EVP, CFO & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,226
-14.35%
|
$11,130
$5.45 P/Share
|
|
Mar 10
2024
|
James Patrick Kelly EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,608
+22.9%
|
-
|
|
Mar 07
2024
|
John Trizzino EVP, CCO and CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,955
-35.29%
|
$69,775
$5.61 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 286K shares |
|---|
| Payment of exercise price or tax liability | 92.9K shares |
|---|---|
| Open market or private sale | 76.2K shares |